A Big Dose of Pharma Plays

Are these 5 drugmakers BUYs or NOT? [Total Wealth] BROUGHT TO YOU BY MANWARD PRESS Buy This, Not That: A Big Dose of 5 Big Pharma Stocks SPONSORED [The Final Piece of Nvidia's AI Puzzle]( [Missing piece of jigsaw puzzle]( Nvidia's Blackwell chip is set to redefine artificial intelligence, but it can't reach its full potential without one crucial component. That's where this secretive startup comes in. Their technology is the backbone of Blackwell's success, and as Nvidia aims for global AI dominance, this little-known company could be the key to unlocking untold riches. [Discover the hidden link in the AI supply chain.]( A Note From Amanda: In this edition of Buy This, Not That... Shah's looking at a sector that outperforms during the months of July and August. But before you dive in... you need to see Shah's just released research on what he's calling "[Undefeated Stocks]( - stocks that produce gains like clockwork. If you're interested in getting his No. 1 pick for August - a stock that has averaged double-digit gains in the month of August for five straight years - [click here](. --------------------------------------------------------------- [Shah Gilani] Shah Gilani Chief Investment Strategist The healthcare sector pumps trillions of dollars through our economy's veins each year. But not all healthcare stocks deserve a spot in your portfolio. From weight loss wonder drugs to household staples... we're putting five pharmaceutical heavyweights to the test. SPONSORED [Nvidia's Secret Partner... This Is The New AI Chip Powerhouse]( [Chatbot conversation]( I bet you've never heard of it... but this newly public company is set to become key to Nvidia's seat on the AI throne. And for now... you can get in while it's still cheap. [Details Here!]( Are their stock charts showing signs of good health... or do they need intensive care? We're looking at a pharma giant with a sky-high P/E ratio... a dividend darling that could be living beyond its means... one that might need to call a Code Blue on its finances... and more. Which of these pharma stocks hands out a prescription for portfolio health? And which ones should be quarantined? It's all in the latest episode of Buy This, Not That... your exclusive guide to the stocks that are worthy of your money - NOW. [Click here]( or on the thumbnail below to dive in. [Video - Buy This, Not That]( [WATCH THE VIDEO (WITH TRANSCRIPT)]( Cheers, Shah SPONSORED [The David to Nvidia's Goliath: Tiny Startup Solving AI's Biggest Challenge]( [CPU concept]( While Nvidia grabs the headlines, a little-known company is quietly reshaping the AI landscape. Their cutting-edge technology is tackling the biggest bottleneck in AI adoption, attracting customers like Intel, AMD, Microsoft, and more. As the AI boom accelerates, this tiny startup could be the ultimate winner. [Get in early on the AI revolution's best-kept secret.]( Want more content like this? [YES]( [NO]( Shah Gilani Shah Gilani is the Chief Investment Strategist of Manward Press. Shah is a sought-after market commentator... a former hedge fund manager... and a veteran of the Chicago Board Options Exchange. He ran the futures and options division at the largest retail bank in Britain... and called the implosion of U.S. financial markets (AND the mega bull run that followed). Now at the helm of Manward, Shah is focused tightly on one goal: to do his part to make subscribers wealthier, happier and freer. You are receiving this email because you subscribed to Total Wealth. To unsubscribe from Total Wealth, [click here](. Need help with your account? [Click here](. Have a question or comment for the editor? [Click here](mailto:mailbag@manwardpress.com). Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Member Services | [14 West Mount Vernon Place | Baltimore, MD 21201](#) North America: [1.800.682.5210](#) | International: [+1.443.353.4263](#) [Website]( | [Privacy Policy]( Keep the emails you value from falling into your spam folder. [Whitelist Total Wealth](. © 2024 Manward Press, LLC | All Rights Reserved Nothing published by Manward Press, LLC should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press, LLC should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.